<DOC>
	<DOCNO>NCT00180089</DOCNO>
	<brief_summary>The purpose study determine whether orale budesonide effective prevention acute gastrointestinal graft-versus-host disease ( GVHD ) follow allogenic stem cell transplantation .</brief_summary>
	<brief_title>Budesonide Prevention Acute Gastrointestinal GVHD Following Allogenic Stem Cell Transplantation</brief_title>
	<detailed_description>The purpose study determine whether orale budesonide effective prevention acute gastrointestinal graft-versus-host disease ( GVHD ) follow allogenic stem cell transplantation .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>plan allogenic stem cell bone marrow transplantation HLA identity ( max . 1 mismatch ) standard GVHD prophylaxis cyclosporin A tacrolimus combine MTX , +/ ATG Campath1H write informed consent history allogenic transplantation vitro Tcell deplete transplant pretreatment budesonide within previous 4 week know intolerance budesonide gastrointestinal infection portal hypertension concomitant infectious disease liver cirrhosis , impair liver function severe mental disorder lack compliance drug alcohol abuse pregnancy , lactation childbearing potential without effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>graft-versus-host disease</keyword>
	<keyword>budesonide</keyword>
	<keyword>stem cell transplantation</keyword>
</DOC>